Regeneron Pharmaceuticals (REGN) Change in Accured Expenses (2009 - 2026)

Regeneron Pharmaceuticals has reported Change in Accured Expenses for 18 years, with the latest figure at $107.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 150.3% year-over-year to $107.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 157.88% YoY), and the FY2025 full-year result was $736.8 million, changed 0.23% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $107.7 million, up from -$24.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $759.2 million in Q3 2025, with the low at -$250.4 million in Q1 2022.
• Average Change in Accured Expenses over 5 years is $120.0 million, with a median of $110.5 million recorded in 2024.
• Year-over-year, Change in Accured Expenses plunged 621.61% in 2022 and surged 460.95% in 2023.
• Tracing REGN's Change in Accured Expenses over 5 years: stood at $347.6 million in 2022, then slumped by 139.9% to -$138.7 million in 2023, then soared by 262.65% to $225.6 million in 2024, then tumbled by 110.95% to -$24.7 million in 2025, then jumped by 536.03% to $107.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $107.7 million (Q1 2026), -$24.7 million (Q4 2025), and $759.2 million (Q3 2025), per Business Quant data.

Peer Comparison